Avalo Therapeutics, Inc. (AVTX)

Avalo Therapeutics Revenue

Avalo Therapeutics had revenue of $59.00K in the twelve months ending March 31, 2026, down -86.62% year-over-year. In the year 2025, Avalo Therapeutics had annual revenue of $59.00K, down -86.62%.

• Revenue (ttm): $59.00K
• Revenue Growth: -86.62%
• P/S Ratio: 12,348.45
• Revenue / Employee: $1,788
• Employees: 33
• Market Cap: 725.93M

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	59.00K	-382.00K	-86.62%
Dec 31, 2024	441.00K	-1.48M	-77.08%
Dec 31, 2023	1.92M	-16.13M	-89.34%
Dec 31, 2022	18.05M	12.65M	234.40%
Dec 31, 2021	5.40M	-1.30M	-19.42%
Dec 31, 2020	6.70M	-51.35K	-0.76%
Dec 31, 2019	6.75M	-278.03K	-3.96%
Dec 31, 2018	7.03M	-20.78M	-74.73%
Dec 31, 2017	27.81M	26.66M	2,312.26%
Dec 31, 2016	1.15M	-	-
Dec 31, 2015	-	-	-
Dec 31, 2014	-	-	-
Dec 31, 2013	-	-	-
Dec 31, 2012	82.76K	-	-

Data Source: Fiscal.ai Last updated: May 13, 2026

Revenue data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 1, 2026

Data Sources Report a data error